We recently identified senescence marker protein 30 as the lactone hydrolyzing enzyme gluconolactonase, which is involved in vitamin C biosynthesis. In this study, we investigated the effects of vitamin C on insulin secretion from pancreatic β cells using senescence marker protein 30/gluconolactonase knockout mice. In intra peritoneal glucose tolerance tests, vitamin C deficient senescence marker protein 30/gluconolactonase knockout mice demonstrated impaired glucose tolerance with significantly lower blood insulin levels at 30 and 120 min post challenge than in wild type mice (p<0.01-0.05). In contrast, vitamin C sufficient senescence marker protein 30/gluconolactonase knockout mice demonstrated signifi cantly higher blood glucose and lower insulin only at the 30 min post challenge time point (p<0.05). Senescence marker protein 30/ gluconolactonase knockout mice showed enhanced insulin sensi tivity regardless of vitamin C status. Static incubation of islets revealed that 20 mM glucose stimulated insulin secretion and islet ATP production were significantly decreased at 60 min only in vitamin C deficient SMP30/GNL knockout mice relative to wild type mice (p<0.05). These results indicate that the site of vitamin C action lies between glycolysis and mitochondrial oxidative phosphorylation, while SMP30 deficiency itself impairs the distal portion of insulin secretion pathway.
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Key Words: vitamin C, insulin, islet, Senescence marker protein 30, gluconolactonase Introduction S enescence marker protein-30 (SMP30), a 34-kDa protein originally identified in rat liver, is a novel molecule with expression that decreases with age in a sex-independent manner. Recently, we determined that SMP30 is gluconolactonase (GNL), which is involved in L-ascorbic acid biosynthesis in mammals. Humans, nonhuman primates, and guinea pigs are unable to synthesize vitamin C (VC) in vivo because there are many mutations in their gulonolactone oxidase gene, which catalyzes the conversion of L-gulono-γ-lactone to L-ascorbic acid. (3) Although the physiological function of SMP30/GNL is still not entirely clear, our studies using SMP30/GNL knockout (KO) mice have revealed that a reduction in SMP30/GNL expression may contribute to ageassociated deterioration of cellular function and the enhanced susceptibility to harmful stimuli in aged tissue.
(4-11) SMP30/GNL KO mice cannot synthesize ascorbic acid and display symptoms of scurvy when fed a VC-deficient diet. (3, 12, 13) Furthermore, SMP30/ GNL KO mice have been used for the study of VC movement and regulation of VC transporter expression. (14) (15) (16) Guinea pigs have long been used for VC research, and the essential role of VC in the release of insulin from pancreatic islets was shown using scorbutic guinea pigs. (17) (18) (19) (20) (21) (22) However, there have been no previous reports on the role of VC in insulin secretion in other animal species. In the present study, we demonstrate impaired glucose tolerance in vivo and abnormal insulin release from pancreatic islets in VC-deficient SMP30/GNL KO mice.
Materials and Methods
Animals. SMP30/GNL KO mice were generated as previously described by gene targeting in C57BL/6 mice.
(4) Male mice were used for all studies. All studies were performed using agematched, wild type (WT) C57BL/6CrSlc mice (Shimizu Laboratory Supplies Co., Ltd., Kyoto, Japan) as controls. Mice were fed VCdeficient chow (CL-2; CLEA Japan, Tokyo Japan) for 8 weeks starting at 7 weeks of age and then divided into two groups: a VCsupplemented (VC (+)) group, and a VC-deficient (VC (−)) group. The VC (+) group had free access to water containing 1.5 g/L VC in 10 µM ethylenediaminetetraacetic acid (EDTA; pH 8.0), whereas the VC (−) group had free access to water containing 37.5 mg/L VC and 10 μM EDTA. Under VC (−) conditions, SMP30/GNL KO mice do not manifest symptoms of scurvy and their body weight gain is similar to that of WT mice. The water was changed every 3 days until the experiment ended. Mice had free access to food, and were maintained on a 12-h light/dark cycle in a temperature-controlled room. At the end of the experiment, mice were killed by an overdose of sodium aminobarbital after an overnight fast, and the pancreas and liver were removed. All experimental procedures were approved by the Committee for Animal Research, Kyoto Prefectural University of Medicine.
Analytical procedures and glucose and insulin tolerance tests. Blood glucose levels were measured using a glucometer (GLUTEST ACE, Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Japan). Intraperitoneal glucose (2 g/kg body weight) and insulin (0.75 U/kg body weight) tolerance tests were performed after 16 h and 7 h fasts, respectively, and blood glucose was measured at the indicated time points. To measure insulin release during glucose tolerance testing, plasma collected at the 0, 30, and 120 min time points was analyzed using an insulin enzyme immunoassay system, the Morinaga Ultra Sensitive Mouse Insulin Assay kit (Morinaga Institute of Biological Science, Inc., Kanagawa, Japan).
Measurement of pancreatic insulin content.
Pancreatic insulin content was determined as previously described. (23) Briefly, a portion of the pancreatic tail was homogenized in acidic ethanol S (0.18 mol/L HCl in 95% ethanol), and extracted for 24 h at 4°C. The homogenate was then centrifuged at 2,000 × g for 15 min. Insulin levels in the supernatant were assayed as described above.
Measurement of total vitamin C levels in the liver.
Livers were homogenized in 14 volumes of 5.4% metaphosphonic acid, and then the homogenate was centrifuged at 21,000 × g for 15 min at 4°C. Ascorbic acid in samples was treated with 350 mM tris(2-carboxyethyl)phosphine hydrochloride to reduce the dehydroascorbic acid to ascorbic acid and analyzed by HPLC using an Atlantis dC18 5 μm column (4.6 × 150 mm, Nihon Waters, Tokyo, Japan). (24) The mobile phase was 50 mM phosphate buffer (pH 2.8), 0.2 g/L EDTA, and 2% methanol at a flow rate of 1.3 mL/min, and electrical signals were recorded using an electrochemical detector with a glassy carbon electrode at +0.6 V.
Static insulin secretion from isolated islets. Pancreatic islets were isolated from VC (+) and VC (−) SMP30/GNL KO and VC (−) WT mice. Islets were isolated using collagenase (Type V collagenase, Sigma, St. Louis, MO), digested in Hanks' buffer, followed by separation of islets from exocrine tissue in a Histopaque (Histopaque 1077, Sigma) gradient. (25) Islets of similar size were hand-picked under a stereomicroscope into triplicate groups (n = 5) of 5 islets each. The islets were preincubated for 60 min at 37°C in Krebs-Ringer bicarbonate HEPES buffer (KRBH, equilibrated with 95% O2 and 5% CO2, pH 7.4) supplemented with 2 mg/ml BSA (fraction V, Sigma) and 2 mM glucose. After preincuation, the islets were incubated with 200 μl of the same buffer for 60 min. After samples were removed from the buffer for measurement of insulin, they were incubated in 20 mM glucose for another 60 min, and then the supernatant was collected. All samples were stored at −80°C until the insulin assay.
ATP measurement from isolated islets. Cultured islets were preincubated at 37°C for 60 min in KRBH with 2 mM glucose and then triplicate batches of 10 islets were incubated in 2 or 20 mM glucose for another 60 min. ATP was extracted from islets using the methods described by Uchizono et al. (26) ATP levels were measured using the Enliten ATP Assay System (Promega, WI) with a bioluminometer (GloMax 20/20n Luminometer, Promega).
Statistical analysis. Data are expressed as means ± SE. Significance was determined by one-way ANOVA with Dunn's multiple comparisons post-hoc. A two-way ANOVA was used to compare glucose and insulin levels at the same time point for the intraperitoneal glucose tolerance test. p<0.05 was considered to be significant.
Results
Body weight, blood glucose, pancreatic insulin content, and total liver vitamin C. There were no differences in body weight, blood glucose, or pancreatic insulin content among the four experimental groups (Table 1) . However, as expected, total liver VC in VC (−) SMP30/GNL KO mice were dramatically lower than that in the other three groups. These results indicate that VC deficiency (ad libitum access to water containing 37.5 mg/L VC) did not affect normal growth as assessed by body weight gain. (Table 1) .
Intraperitoneal glucose tolerance test. Blood glucose levels 30 min after glucose administration were significantly higher in VC (+) SMP30/GNL KO mice than in VC (−) or VC (+) WT mice (p<0.05, Fig. 1 ). In addition, blood glucose levels in VC (−) SMP30/GNL KO mice 30, 60, and 120 min after glucose administration were significantly higher than those of WT mice in either group (p<0.01, Fig. 1 ). However, there were no significant differences in blood glucose levels between VC (−) and VC (+) SMP30/GNL KO mice at any time point. VC supplementation did not affect glucose tolerance in WT mice. A significant increase in area under the curve (AUC, 0-120 min) was detected only in VC (−) SMP30/GNL KO mice when compared to VC (−) and VC (+) WT mice (p<0.01, Fig. 1 ). No significant difference in AUC was detected between VC (−) and VC (+) SMP30/GNL KO mice.
There were no significant differences in fasting insulin levels among the four groups. However, insulin levels 30 min postglucose were significantly lower in VC (−) and VC (+) SMP30/ GNL KO mice than in either group of WT mice (p<0.01 and <0.05, respectively, Fig. 2 ). Insulin levels 120 min post-glucose were lower in VC (−) SMP30/GNL KO mice than in the other three groups; however, the difference was significant only when compared to VC (+) WT mice (p<0.05, Fig. 2 ). AUC (0-120 min) for VC (−) SMP30/GNL KO mice was significantly lower than that for VC (−) and VC (+) WT mice (p<0.05, Fig. 2) ; however, while VC (+) SMP30/GNL KO mice also showed a trend towards decreased AUC, it was not significant.
Insulin tolerance test. We next assessed insulin sensitivity using an insulin tolerance test. Blood glucose levels in both groups of SMP30/GNL KO mice were significantly lower than those in WT mice after 30 and 60 min, indicating high peripheral insulin sensitivity (Fig. 3) . In VC (−) SMP30/GNL KO mice, the decrease in blood glucose levels was significant at 30 and 60 min. VC deficiency did not induce significant changes in insulin sensitivity in SMP30/GNL KO or WT mice.
Measurement of insulin secretion and ATP from isolated
islets. To confirm β-cell dysfunction in SMP30/GNL KO mice, we measured glucose-stimulated insulin secretion in isolated islets. As described above, VC deficiency did not affect liver VC content or glucose tolerance in WT mice, so we used islets from VC (−) WT mice as a control. Similar to the in vivo results, insulin secretion from VC (−) SMP30/GNL KO islets incubated in 20 mM glucose for 60 min was significantly reduced compared to that from VC (+) SMP30/GNL KO and WT islets (p<0.05, Fig. 4) . The insulin secretory response in VC (+) SMP30/GNL KO islets was similar to that in WT islets (Fig. 4) . This finding may indicate that impaired insulin secretion in response to glucose in VC (+) SMP30/GNL KO islets is due to selective impairment of the early phase of insulin secretion (~30 min) but that by 60 min after glucose stimulation this impairment is no longer evident. To support this assumption, a previous report by our group demonstrated significantly lower insulin secretion in response to 20 mM Vitamin C content, liver (µg/g tissue) 143.7 ± 7.7 9.9 ± 1.3* 169.4 ± 9.9 160.2 ± 8.5
glucose after 15 min in islets from VC-supplemented SMP30/ GNL KO mice compared to WT mice. (10) There were no significant differences in islet ATP content in 2 mM glucose among the three groups. ATP content in 20 mM glucose was significantly decreased in VC (−) SMP30/GNL KO islets compared to VC (+) SMP30/GNL KO or WT islets (p<0.05). ATP content in 20 mM glucose in VC (+) SMP30/GNL KO islets was similar to that in WT islets (Fig. 5) .
Discussion
This report has shown that, in SMP30/GNL KO mice, VC deficiency without obvious signs of scurvy worsened glucose tolerance and impaired insulin secretion after a glucose load. Our in vitro data from isolated islets confirmed that VC deficiency was responsible for the reduced insulin secretory response to glucose. Furthermore, the observed decrease in glucose-stimulated ATP generation in pancreatic islets indicates that the site of VC action lies between glycolysis and mitochondrial oxidative phosphorylation. The modestly impaired glucose tolerance with an impairment of acute insulin secretion seen here in VC-supplemented SMP30/ GNL KO mice is comparable to that in our previous report, which demonstrated the role of SMP30/GNL in glucose homeostasis without looking at the effects of VC deficiency. (10) The essential role of VC in glucose-stimulated insulin secretion was originally reported by Sigal and King, (17) and Banerjee, (18) who looked at scorbutic guinea pigs. In a subsequent study, it was shown that decreased insulin release from scorbutic islets was not due to decreased insulin synthesis but rather due to abnormal insulin secretion. (19, 20) Further studies have demonstrated that VC is an essential cofactor for the activation of mitochondrial glycerol-3-phosphate dehydrogenase (mGPDH), a key enzyme for the glycerol phosphate NADH shuttle in pancreatic β-cells. They assumed that mGPDH inactivation due to VC deficiency would cause a reduction in shuttling of cytosolic NADH generated from glycolysis and pyruvate into mitochondria, leading to a reduction in ATP generation and thereby reducing insulin release. (21, 22) The present data from our study of VC-deficient SMP30/GNL KO mice are consistent with these previous studies in scorbutic guinea pigs.
Because SMP30 is abundant in the kidney and also present in lesser amounts in other organs, (27) this protein is presumed to have some function other than VC synthesis, which does not occur at all these sites. Our previous study of VC-supplemented SMP30/ GNL KO mice suggested that SMP30 deficiency itself induced dysregulation of Ca 2+ homeostasis, resulting in impairment of glucose-induced Ca 2+ influx and of Ca
2+
-dependent signaling pathways, which are involved in the peripheral portion of the insulin secretion pathway. These results suggest that SMP30 could be implicated in the impairment of β-cell function with age in humans.
(10) Therefore, it should be noted that the decreased insulin secretion demonstrated here in VC-deficient SMP30/GNL KO mice is a consequence of impairment of both the peripheral and proximal portions of the insulin secretion pathway. Surprisingly, there have been no previous reports on the effects of VC deficiency on insulin sensitivity. In the present study, despite impaired glucose tolerance, SMP30/GNL KO mice showed greater insulin sensitivity, regardless of VC status. Although the mechanism has not been studied, inactivation of mGPDH due to VC deficiency could partially explain this phenomenon, considering that previous reports showed that mGPDH KO mice manifest increased insulin sensitivity and impaired insulin secretion, similar to SMP30/GNL KO mice. (28, 29) The inability of guinea pigs to synthesize VC due to mutations in the L-gulono-g-lactone oxidase gene is well known.
(30) Because they share this trait with humans, guinea pigs have long been used for VC research. Most of our knowledge of the role of VC in insulin secretion and glucose tolerance in vivo has come from studies of VC-deficient guinea pigs. (17) (18) (19) (20) (21) (22) This is the first study examining insulin secretion in a VC-deficient mouse model. These laboratory animals have advantages over guinea pigs in terms of breeding, care, and size. L-gulono-g-lactone oxidase KO mice, which cannot synthesize VC in vivo, represent another VCdeficient mouse model. (31) In summary, VC-deficient SMP30/GNL KO mice have modestly impaired glucose tolerance with impaired acute insulin secretion due to decreased glucose-stimulated ATP production in β-cells. These results suggest that the site of VC action is between glycolysis and mitochondrial oxidative phosphorylation. SMP30/GNL KO mice are a useful VC-deficient animal model, and further studies will bring us new insights into the mechanism of insulin secretion in pancreatic β-cells. 
